Creative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 14.6% and free cash flow fell 27.1%, each against the same quarter a year earlier.
Follow CELZ
Creative Medical Technology Holdings, Inc. (CELZ) P/E ratio
Creative Medical Technology Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.6× (March 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. | n/m |
| CANF Can-Fite Biopharma Ltd compare | n/m |
| BGMS Bio Green Med Solution, Inc. compare | n/m |
| IMNN Imunon, Inc. compare | n/m |
| ORGS Orgenesis Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)